News

A Chinese study reveals that secondhand smoke exposure significantly increases the risk of early-onset myopia in children

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

Researchers at the Korea Advanced Institute of Science and Technology demonstrated the next-generation strategy for sustainable synthesis

KAIST researchers unveil a new microbial strain for efficient, eco-friendly lutein production.

The tool is designed to help with the application of mono-dose, dry eye eyedrop vials more easily and accurately.

New tariffs threaten the optical industry, prompting urgent reevaluation of sourcing strategies and pricing as deadlines approach for affected countries.

Alcon’s Voyager is a fully automated, noncontact treatment approach that delivers 120 laser pulses through the limbus of the trabecular meshwork.

MCO-010 is a gene-agnostic therapy for retinitis pigmentosa.

The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation.

Krystal Biotech initiates EMERALD-1 trial for KB801, a redosable eye drop gene therapy.

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

RetinalGeniX partners with Labcorp to enhance genetic testing and retinal imaging, aiming for early disease detection and improved patient care.

Cannabis has been shown to reduce microglial activity, expression of inflammatory cytokines and retinal neurotoxicity

Catch up on this week's highlights in retina.

KALA Bio completes enrollment in CHASE trial, advancing KPI-012 for treating persistent corneal epithelial defects. Topline results are expected by the end of Q3 2025.

Careful management of patient expectations is key to achieving optimal outcomes.

EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in vision and safety.

Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.

The VISTA trial is evaluating and comparing 2 dose levels of laru-zova with an untreated control group for the treatment of X-linked retinitis pigmentosa (XLRP).

Alcon's Clareon Panoptix Pro IOL enhances cataract surgery with advanced light utilization and low visual disturbance.

Atsena Therapeutics expands its ATSN-201 trial for X-linked retinoschisis, a step toward the first gene therapy treatment.

How artificial intelligence could enhance clinical trials.

The trifocal IOL is designed to deliver lower light scatter and higher-reported light utilisation

Ophthalmologists discuss the most impactful advancements reshaping patient care over five decades.

A hope for reducing treatment burden for wet age-related macular degeneration with a sustained-release vorolanib intravitreal insert

Preliminary results of PST-611-CT1 are anticipated early 2026, subject to patient recruitment.